{"id":"https://openalex.org/W1990209210","doi":"https://doi.org/10.1016/s1359-6349(06)70410-4","title":"405 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies","display_name":"405 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies","publication_year":2006,"publication_date":"2006-11-01","ids":{"openalex":"https://openalex.org/W1990209210","doi":"https://doi.org/10.1016/s1359-6349(06)70410-4","mag":"1990209210"},"language":"en","primary_location":{"id":"doi:10.1016/s1359-6349(06)70410-4","doi":"https://doi.org/10.1016/s1359-6349(06)70410-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1359-6349(06)70410-4","pdf_url":null,"source":{"id":"https://openalex.org/S13410216","display_name":"European Journal of Cancer Supplements","issn_l":"1359-6349","issn":["1359-6349","1878-1217"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","jufo-1","norway-1","poland-100","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer Supplements","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Kurzrock","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022436659","display_name":"Luis H. Camacho","orcid":"https://orcid.org/0000-0003-1856-8641","observed_orcids":["https://orcid.org/0000-0003-1856-8641"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Camacho","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Hong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053460346","display_name":"Chaan S. Ng","orcid":"https://orcid.org/0000-0001-9261-7021","observed_orcids":["https://orcid.org/0000-0001-9261-7021"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Ng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071718298","display_name":"Linda A. Janisch","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Janisch","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068268371","display_name":"Mark J. Ratain","orcid":"https://orcid.org/0000-0002-0938-4392","observed_orcids":["https://orcid.org/0000-0002-0938-4392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M.J. Ratain","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5003826371","display_name":"Ravi Salgia","orcid":"https://orcid.org/0000-0001-9643-7626","observed_orcids":["https://orcid.org/0000-0001-9643-7626"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Salgia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":0,"currency":"USD","value_usd":0},"apc_paid":null,"fwci":0.2702,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.52863601,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"4","issue":"12","first_page":"124","last_page":"125"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.4507000148296356,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.4507000148296356,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.11710000038146973,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.09889999777078629,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cabozantinib","display_name":"cabozantinib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/vegfr-tyrosine-kinase-inhibitors","display_name":"VEGFR inhibitors","score":0.6809999942779541},{"id":"https://openalex.org/keywords/met-inhibitors","display_name":"MET inhibitors","score":0.8690000176429749},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.5210000276565552},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.8410000205039978},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6340000033378601},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.6779999732971191},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9959999918937683},{"id":"https://openalex.org/keywords/hepatocyte-growth-factor","display_name":"hepatocyte growth factor","score":0.8669999837875366},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.7639999985694885},{"id":"https://openalex.org/keywords/prostate-development","display_name":"prostate development","score":0.6179999709129333},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.6579999923706055}],"concepts":[{"id":"https://openalex.org/C2776996007","wikidata":"https://www.wikidata.org/wiki/Q2399112","display_name":"Hepatocyte growth factor","level":3,"score":0.9066793918609619},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7425267696380615},{"id":"https://openalex.org/C101544691","wikidata":"https://www.wikidata.org/wiki/Q420511","display_name":"Receptor tyrosine kinase","level":3,"score":0.718187689781189},{"id":"https://openalex.org/C2910739307","wikidata":"https://www.wikidata.org/wiki/Q5005897","display_name":"Hepatocyte Growth Factor Receptor","level":5,"score":0.6341418027877808},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6176655292510986},{"id":"https://openalex.org/C2776235491","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate","level":3,"score":0.610685408115387},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5527660250663757},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5481963753700256},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.542053759098053},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4423459470272064},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41365480422973633},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4022969603538513},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39844027161598206},{"id":"https://openalex.org/C2780467284","wikidata":"https://www.wikidata.org/wiki/Q5005897","display_name":"C-Met","level":4,"score":0.392948180437088},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3522699177265167}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s1359-6349(06)70410-4","doi":"https://doi.org/10.1016/s1359-6349(06)70410-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1359-6349(06)70410-4","pdf_url":null,"source":{"id":"https://openalex.org/S13410216","display_name":"European Journal of Cancer Supplements","issn_l":"1359-6349","issn":["1359-6349","1878-1217"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","jufo-1","norway-1","poland-100","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer Supplements","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1520841340","https://openalex.org/W2899943563","https://openalex.org/W2129696872","https://openalex.org/W160267242","https://openalex.org/W2010700447","https://openalex.org/W7035919519","https://openalex.org/W1992220862","https://openalex.org/W1274170188","https://openalex.org/W1992293890","https://openalex.org/W2994995322"],"abstract_inverted_index":null,"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}